COVID Cases To Date

- (1941) TOTAL CASES
- (10) ACTIVE CASES
- TOTAL HOSPITALIZATIONS: (43)
- CURRENT HOSPITALIZATIONS: (0)
- DEATHS: 4
Influenza and RSV

- Despite seeing lower positive cases of COVID, KMC is diagnosing many cases of Influenza and RSV (Respiratory Syncytial Virus)

- Last week many KMC staff or their families were affected by COVID, Influenza, or RSV.
- This left the clinic short-staffed, the Nursing Department alone was down 8 staff members.
The KMC providers (5) and nursing staff saw

322 Patients

146 patients were seen in COVID/Respiratory Unit
North Coast Testing Partnership

- North Coast Testing Partnership offered Hoopa Valley Tribes COVID-19 Surveillance Testing at no cost.
- 10/31/22 NCTP Contract ended with the State.
- NCTP will no longer be offering COVID-19 Surveillance Testing Lab Services.
The current recommendation is not to do surveillance testing of unvaccinated individuals.

What are the recommendations of the Hoopa Valley Tribe?

Discussions are ongoing with Dr. Smith, Tribal Insurance, calls are into OES, and myself.

Delta

Omicron

June
July
August
September
October
November
December
January
February
March
April
May
June
July
August
September
October
November
December
January
February
March
April
May
June
July
August
September
COVID-19 Positive Cases
1/1/22 through 11/30/22

- January: 353
- February: 180
- March: 17
- April: 19
- May: 93
- June: 94
- July: 57
- August: 163
- September: 60
- October: 109
- November: 52

Omicron
Delta
KMC has the regular Flu Vaccine.

- Appointments are being made to receive the vaccine and see a provider at the same time.
- This will allow the provider to have an opportunity to see the patient and connect individuals with chronic disease processes to care, refer for labs, and connect to follow up care.
- Revenue will be generated by the appointment
Seasonal Flu Vaccine

- Flu Vaccine Clinic Dates - TBA
- Flu Vaccine given at the Diabetes Walk on October 8, 2022. 43 Flu Vaccines given
Bivalent Booster Vaccine

- The bivalent COVID-19 vaccines, include an mRNA component of the original strain to provide an immune response that is broadly protective against COVID-19 and an mRNA components in common between the Omicron variant BA.4 and BA.5 to provide better protection against COVID-19 cased by the Omicron variant.
Modern Bivalent Booster

Authorized uses:

- 6 years and above
- Completed a COVID vaccine primary dose series.
- Eligible if it has been 2 months since your primary 2 dose series.
Moderna COVID-19 Vaccine
At-A-Glance

Scheduling Doses
Graphics below provide an overview for the number of doses of vaccine based on the type of dose (primary versus booster), recipient's age and health status. Review CDC's interim COVID-19 Immunization Schedule for detailed clinical guidance when scheduling doses.

For Most Persons
- Moderna (ages 6 months - 4 years)
  - Primary in 4-8 weeks
  - Primary

- Moderna (ages 5 years and older)
  - Primary in 4-8 weeks
  - Primary
  - Bivalent mRNA Booster

For Moderately or Severely Immunocompromised Persons
- Moderna (ages 6 months - 4 years)
  - Primary in 4 weeks
  - Primary
  - Primary

- Moderna (ages 5 years and older)
  - Primary in 4 weeks
  - Primary
  - Primary
  - Bivalent mRNA Booster

* Administer an age-appropriate mRNA booster (i.e., Pfizer-BioNTech for people age 1 year and older; Pfizer-BioNTech or Moderna for people ages 6 years and older) for people who previously received a nonvalent mRNA booster dose. For bivalent booster dose, administer at least 2 months after the last nonvalent booster dose.
# Moderna COVID-19 Vaccine At-A-Glance

## Preparation and Administration Basics
Find additional guidance on preparing and administering vaccine properly at:
- Moderna COVID-19 Vaccine: [CDC](https://www.cdc.gov)
- Moderna COVID-19 Vaccine: [FDA](https://www.fda.gov)

### Vial Cap Color
- **Monovalent Blue Cap**
- **Monovalent Blue Cap with magenta-bordered label**
- **Monovalent Red Cap**
- **Bivalent Blue Cap**

### Ages
- **6 months through 5 years**
- **6 through 11 years**
- **12 years and older**
- **6 years and older**

### Beyond-use Date/Time
- After first puncture, use within 12 hours
- If using a vial for the 1st time, record the date and time the vial was punctured.

**NOTE:** The beyond-use time (12 hours) replaces the manufacturer's expiration date but NEVER extends it. Always use the earliest date. Do NOT use vaccine if the expiration date or beyond-use time has passed.

### Administration
- COVID-19 vaccine may be administered at the clinical visit as other vaccines.
- **Do not** “pool vaccine” from more than 1 vial to obtain a dose. If a full dose cannot be withdrawn, discard the vial and any remaining vaccine.

### Recipient's Age
- **6 months through 5 years of age**
- **6 through 11 years**
- **12 years or older**
- **6 years or older**

### Use
- **Primary series:** 25 µg/0.25 mL
- **Primary series:** 50 µg/0.5 mL
- **Primary series:** 100 µg/0.5 mL
- **Booster dose only:** 6-11 years: 25 µg/0.25 mL; 12 years and older: 50 µg/0.5 mL

### Needle Gauge and Length
- **IM injection:** 22-25 gauge, 1”
- **IM injection:** 22-25 gauge, 1½”

**Site:**
- **6 months – 2 years of age:** Ventral lateralis muscle in the anterolateral thigh
- **3 – 5 years of age:** Deltoid muscle in the upper arm
- **6 – 12 years of age:** Deltoid muscle in the upper arm
- **12 years or older:** Deltoid muscle in the upper arm

---

*The deltoid muscle in the upper arm may be used if the muscle mass is adequate.*

*Ventral lateralis muscle in the anterolateral thigh may be used.*
Pfizer Bivalent Booster

Authorized uses:

- 5 years of age and up
- Completed a COVID vaccine primary dose series.
- Eligible if it has been 2 months since your primary 2 dose series.

- KMC has Pfizer Bivalent Booster Vaccine
Pfizer-BioNTech COVID-19 Vaccine

Scheduling Doses

Graphics below provide an overview for the number of doses of vaccine based on the type of dose (primary versus booster), recipient’s age and health status. Review CDC’s Interim COVID-19 Immunization Schedule for detailed clinical guidance when scheduling doses.

For Most Persons

Pfizer-BioNTech
(ages 6 months–4 years)

In 3-8 weeks

PRIMARY

In at least 8 weeks

PRIMARY

For Moderately or Severely Immunocompromised Persons

Pfizer-BioNTech
(ages 6 months–4 years)

In 3 weeks

PRIMARY

In at least 8 weeks

PRIMARY

In at least 4 weeks

PRIMARY

BIVALENT mRNA BOOSTER*

* Administer an age-appropriate mRNA booster (i.e., Pfizer-BioNTech for people ages 12 years and older; Moderna for people ages 6 years and older) for people who previously received a monovalent booster dose. The bivalent booster dose is administered at least 2 months after the last monovalent booster dose.
### Pfizer-BioNTech COVID-19 Vaccine

#### Preparation and Administration Basics
Find additional guidance on preparing and administering vaccine properly:
- Administration of Pfizer-BioNTech COVID-19 Vaccines | CDC
- Vaccine Administration Resource Library | CDC
- Pfizer-BioNTech COVID-19 Vaccines | FDA
- Pfizer-BioNTech COVID-19 Vaccine | covidvaccine.com

#### Preparation

<table>
<thead>
<tr>
<th>Vial cap color</th>
<th>Monovalent Maroon Cap</th>
<th>Monovalent Orange Cap</th>
<th>Bivalent Orange Cap</th>
<th>Monovalent Gray Cap</th>
<th>Bivalent Gray Cap</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ages</td>
<td>6 months through 4 years</td>
<td>5 through 11 years</td>
<td>12 years and older</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diluent</td>
<td>2.2 ml per vial</td>
<td>1.3 ml per vial</td>
<td>1.3 ml per vial</td>
<td>No diluent</td>
<td>No diluent</td>
</tr>
<tr>
<td>Beyond-use date/time</td>
<td>After mixing with diluent, use within 12 hours.</td>
<td>After 1st puncture, use within 12 hours.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Do NOT use a punctured vial after 12 hours.*

**Note:** The beyond-use time (12 hours) replaces the manufacturer's expiration date but NEVER extends it. Always use the earliest date. Do NOT use vaccine if the expiration date or beyond-use time has passed.

#### Administration
- COVID-19 vaccine may be administered at the clinical visit as other vaccines.
- Do NOT “pool vaccine” from more than 1 vial to obtain a dose. If a full dose cannot be withdrawn, discard the vial and any remaining vaccine.

<table>
<thead>
<tr>
<th>Recipient's Age</th>
<th>Use</th>
<th>Administer</th>
<th>Route</th>
<th>Needle gauge and length</th>
<th>Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 months through 4 years</td>
<td>Monovalent Maroon cap and maroon bordered label</td>
<td>Primary dose 3 µg/0.2 mL</td>
<td>IM injection</td>
<td>22–25 gauge, 1”</td>
<td>6 months – 2 years of age: Vastus lateralis muscle in the anterolateral thigh; 3 years and older: Deltoid muscle in the upper arm</td>
</tr>
<tr>
<td>5 – 11 years</td>
<td>Monovalent Orange cap and orange bordered label</td>
<td>Primary dose 10 µg/0.2 mL</td>
<td>IM injection</td>
<td>22–25 gauge, 1”</td>
<td>Deltoid muscle in the upper arm</td>
</tr>
<tr>
<td>12 years of age and older</td>
<td>Bivalent Orange cap and orange bordered label</td>
<td>Booster dose 10 µg/0.2 mL</td>
<td>IM injection</td>
<td>22–25 gauge, 1”</td>
<td>Deltoid muscle in the upper arm</td>
</tr>
<tr>
<td></td>
<td>Monovalent Gray cap and gray bordered label</td>
<td>Primary dose 30 µg/0.3 mL</td>
<td>IM injection</td>
<td>22–25 gauge, 1 – 11/2”</td>
<td>Deltoid muscle in the upper arm</td>
</tr>
<tr>
<td></td>
<td>Bivalent Gray cap and gray bordered label</td>
<td>Booster dose 30 µg/0.3 mL</td>
<td>IM injection</td>
<td>22–25 gauge, 1 – 11/2”</td>
<td>Deltoid muscle in the upper arm</td>
</tr>
</tbody>
</table>
Monkeypox is a disease caused by infection with the monkeypox virus. Monkeypox is part of the same family of viruses as the virus that causes smallpox.

Symptoms Include:
- Fever
- Chills
- Swollen Lymph Nodes
- Muscle Aches and Backpains
- Exhaustion
- Headache
- Respiratory symptoms, sore throat, nasal congestion, or cough.
- Rash, may initially look like pimples or blisters and may be painful or itchy.
How is Monkeypox spread:

- Skin to skin contact
- By touching objects, fabrics, surfaces that have been used by someone with monkeypox or by contact with respiratory secretions.
Vaccine:
Jynneos Vaccine – FDA Approved

Eligibility: High Risk Population 18 years of age and older.

KMC has 16 doses available. 4 identified high risk patients will be scheduled per day to administer the vaccine.
Humboldt County Health Department has housed 1 course of TPOXX treatment with Kimaw Medical Center, in the event that an individual in our KT area develops monkeypox.
Individuals can experience returning illness, recurring health problems, or a range of new symptoms four or more weeks after having COVID-19. This is referred to as post-COVID conditions.

Anyone can develop post-COVID conditions including those that were asymptomatic or had mild symptoms.
Long COVID Symptoms

- Brain Fog
- Difficulty breathing or shortness of breath
- Post-exertional malaise
- Cough
- Chest or stomach pain
- Headache
- Heart palpitations
- Joint or muscle pain
- Multiorgan Effects (including heart, lung, kidney, skin, and brain functions)

- Pins-and-needles feeling
- Diarrhea
- Sleep problems
- Fever
- Lightheadedness
- Rash
- Mood Changes
- Changes in menstrual Period Cycle

- 10% to 30% of COVID-19 positive patients experience the after effects of the virus.
COVID Therapeutics

Evushield
- IM Therapy
- K’ima:w Medical Center

Paxlovid
- Oral Therapy
- K’ima:w Medical Center
COVID Vaccine & Boosters Available at KMC

- **Vaccine & Booster Clinics**
  - Thursdays Children
    6 months to 17 yrs
  - Fridays Adults

- **By Appointment Call:**
  - 530-625-4261
  - Ext. 0221 or 0259
Effective January 19th order free home Covid19 tests:
http://www.covidtesting.gov

**KMC**
Monday-Friday 8:40-4:30
By appointment
625-4261 Ext 0218

**OptumServe**
Thursdays 10:00-3:00
Hoopa Fire Department
Limited supply of Quidel COVID Home Tests Available
https://quickvueathome.com/